Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

pharmacogenomics 4860 > Medical Oncology (Final Exam) > Flashcards

Medical Oncology (Final Exam) Flashcards

1
Q

these are used to treat ________
5-Fluorouracil (FLUOROURACIL)
Capecitabine (XELODA)
Irinotecan (CAMPTOSAR)
Cetuximab (ERBITUX)
Panitumumab (VECTIBIX)
Pembrolizumab (KEYTRUDA)
Nivolumab (OPDIVO)

A

colorectal cancer
* 5 capelin I caught Panned Pecked Nivea

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

this is used for treatment of ardenocarcinoma of colon and rectum administered in combination with leucovorin alone or in combination with leucovorin and oxaliplatin or irinotecan. Gene involved is DPD*2A / splicing mutation

A

5-Fluorouracil (FLUOROURACIL)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

this is used for treatment of metastatic colorectal cancer when treatment with fluorpyrimidine therapy alone is preferred. Gene involved is DPD*2A

A

Capecitabine (XELODA)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

this is used for treatment of metastatic colorectal cancer in combination with 5-FU and leucovorin. Gene involved is UGT1A1*28

A

Irinotecan (CAMPTOSTAR)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

this is used to treatment of RAS wild-type, EGFR-expressing metastatic colorectal cancer. Genes involved include KRAS/NRAS/EGFR

A

Cetuximab (ERBITUX)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

this used for treatment of wild-type KRAS/NRAS metastatic colorectal cancer. Genes involved include KRAS/NRAS/EGFR

A

Panitumumab (VECTIBIX)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

regarding Cetuximab (ERBITUX) and Panitumumab (VECTIBIX), mutational analysis should include KRAS and NRAS codons 12 and 13 of exon __

A

2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

regarding Cetuximab (ERBITUX) and Panitumumab (VECTIBIX), mutational analysis should include KRAS and NRAS codons 59 and 61 of exon __

A

3

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

regarding Cetuximab (ERBITUX) and Panitumumab (VECTIBIX), mutational analysis should include KRAS and NRAS codons 117 and 146 of exon __

A

4

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

this is used for treatment of unrespectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer and PD-L1 (CD274) expression that has progressed following Tx with fluoropyrimidine, oxaliplatin and irinotecan. Genes involved include MSI/MLH1/MSH2/MSH6/PMS2/CD274

A

Pembrolizumab (KEYTRUDA)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

this is used for treatment of micro satellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metatstatic colorectal cancer and PD-L1 (CD274) expression that has progressed following Tx with a fluoropyrimidine, oxaliplatin and irinotecan. Genes involved include MSI/MLH1/MSH2/MSH6/PMS2/CD274

A

Nivolumab (OPDIVO)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

these two drugs are used to treat KRAS G12C-mutated locally advanced or metastatic lung cancer

A

Sotorasib (LUMAKRAS) and Adagrasib (KRAZATI)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

these two drugs are used to treat lung cancer where tutors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations

A

gefitinib (IRESSA) and Erlotinib (TARCEVA)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

true/false: getfitinib (IRESSA) and Erlotinib (TARCEVA) is effective for exon 20 mutations

A

false

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

these two drugs are used to treat lung cancer where tutors have non-resistant EGFR mutations including exon 19 deletions or exon 21 (L858R) substitution mutations

A

Afatinib (GILOTRIF) and Dacomitinib (VIZIMPRO)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

true/false: Afatinib (GILOTRIF) and Dacomitinib (VIZIMPRO) are effective for exon 20 mutations

A

false

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

this is used to treat lung cancer where tutors have EGFR exon 19 deletions or exon 21 L858R mutations or treatment of metastatic EGFR T790M-positive lung cancer where disease has progressed on or after EGFR TKI Tx

A

Osimertinib (TAGRISSO)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

true/false: Osimertinib (TAGRISSO) is effective for exon 20 mutations

A

true

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

this is used to treat locally advanced lung cancer with EGFR exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy

A

Mobocertinib (EXKIVITY)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

true/false: Mobocertinib (EXKIVITY) is effective for exon 20 mutations

A

true

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

this is used for treatment of lung cancer that is ALK positive or ROS1 positive

A

Crizitonib (XALKORI)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

this is used for treatment of ALK-positive lung cancer that have inadequate response to crizotinib

A

Certinib (ZYKADIA)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

these two drugs are used for treatment of ALK-positive lung cancer that has progressed with crizotinib. more potent and selective second generation ALK inhibitors

A

Alectinib (ALECENSA) and Brigatinib (ALUNBRIG)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

this is used for treatment of ALK-positive lung cancer that has progressed on crizotinib, certinib and/or alectinib

A

Lorlatinib (LORBRENA)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

this is used for treatment of lung cancer with EGFR/ALK aberrations with disease progression on previous co-therapy

A

Ramucirumab (CYRAMZA)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

this is used for treatment of lung cancer where tutors are ROS1-positive or have a neurotrophic tyrosine receptor kinase (NRTK) gene fusion

A

Entrectinib (ROZLYTREK)
* ROZ and TREK mimic genes affected (ROS1 and N”TRK”

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

this is used for treatment of lung cancer with BRAF V600E/K mutation. may also have an affect in patients with G6PD deficiency

A

Dabrafenib (TAFINLAR)
* BRAF gene, daBRAFenib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

these two drugs are used for treating lung cancer where tumors have mutations that leads to MET exon 14 skipping

A

Capmatinib (TABRECTA) and Tepotinib (TEPMETKO)
* second drug has MET in name therefore MET gene

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

these two drugs are used to treat RET-fusion positive lung cancer

A

Selpercatinib (RETEVMO) and Pralsetinib (GAVRETO)
* RET gene, RET in brand names

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

these three drugs treat lung cancer where tumors have high PD-L1 (CD274) expression with no EGFR or ALK genomic tumour aberrations

A

Pembrolizumab (KEYTRUDA) and Nivolumab (OPDIVO) and Atezolizumab (TECENTRIQ)
* pecking Nivea causes atopic dermatitis *

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

this drug treats lung cancer where tumors have high PD-L1 (CD274) expression with no EGFR, ALK or ROS1 aberrations

A

Cemiplimab (LIBTAYO)
* pecking Nivea causes atopic dermatitis *

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

these two drugs treats lung cancers that express (not high levels) PD-L1 (CD274) with no EGFR or ALK genomic tumour aberrations

A

Durvalumab (IMFINZI) and Ipilimumab (YERVOY)
* pecking Nivea causes atopic dermatitis *

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

these twi drugs are used to treat lung cancer with no EGFR or ALK genomic tumour aberrations

A

Pemetrexol (ALIMTA) and Tremelimumab (IMJUDO)
* pem trem *

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

these two drugs are indicated for breast cancer and are associated with the DPD gene mutation

A

5-Fluorouracil (FLUOROURACIL) & Capecitabine (XELODA)
* 5 capelin * <- same as colorectal cancer tx

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

this drug is used for treatment of estrogen receptor positive metastatic breast cancer. mutation/clinical utility is ESR1/ESR2/CYP2D6. this is also a prodrug

A

Tamoxifen (NOLVADEX)
* ik CYP2D6 therefore seen tamoxifen in practice

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

this drug is used for tx of estrogen receptor positive metastatic breast cancer. gene/clinical utility is ESR1/ESR2

A

Toremifene (FARESTON)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

this drug is used for tx of post-menopausal women with ER-postiive early breast cancer who have received initial adjuvant tamoxifen therapy. Mutation/clinical utility is ESR1/ESR2

A

Exemestane (no brand name)

38
Q

this drug is used two drugs are used for tx of post-menopausal women with HR-postiive early breast cancer or advanced breast cancer. Mutation/clinical utility is ESR1/ESR2/PGR

A

Anastrozole & Letrozole (FEMARA)
* Ana Letgo

39
Q

this is used for treatment of HR-positive, HER-negative advanced breast cancer in post-menopausal women not previously treated with endocrine therapy. mutation/clinical utility is ESR1/ESR2/PGR/ERBB2

A

Fulvestrant (FASLODEX)
* full even palpating ribs *

40
Q

this is used for treatment of post-menopausal women with advanced HR-positive, HER2-negative breast cancer in combination with exemestane after failure of tx with anastrozole or letrozole. mutation/clinical utility is ESR1/ESR2/PGR/ERBB2

A

Everolimus (AFINITOR)
* full even palpating ribs *

41
Q

these two drugs are used for treatment of HR-postiive, HER2-negative advanced or metastatic breast cancer. mutation/clinical utility is ESR1/ESR2/PGR/ERBB2

A

Palbociclib (IBRANCE) & Ribociclib (KISQALI)
* full even palpating ribs *

42
Q

this is used for tx of women with HR-positive, HER2-negative breast cancer and a high Ki-67 (early) biomarker score as a mono therapy or in combination with other medications. mutation/clinical utility is ESR1/ESR2/PGR/ERBB2/MKI67

A

Abemaciclib (VERZENIO)
* Abe *

43
Q

this is used for tx of HR-positive, HER2-negative, PIK3CA-mutated metastatic breast cancer following progression on an endocrine-based regimen in post-menopausal women and men. mutation/clinical utility is ESR1/ESR2/PGR/ERBB2/PIK3CA

A

Alpelisib (PIQRAY)
* Alp*

44
Q

these two drugs are used for tx of deleterious or suspected deleterious gremlin BCRA-mutates (gBCRAm) HER2-negative breast cancer. mutation/clinical utility is ERBB2/BCRA1/BCRA2`

A

olaparib (LYNPARAZA) & talazoparib (TALZENNA)
* Olaf talks *

45
Q

this drug is sued to treat HER2-positive metastatic breast cancer
mutation/clinical utility is ESR1/ESR2/PGR/ERBB2

A

Trastuzumab (HERCEPTIN)

46
Q

this drug is used to treat HER2-positive metastatic breast cancer who have not received prior anti-HER2 tx or chemotherapy in combination with other medications. mutation/clinical utility is ESR1/ESR2/PGR/ERBB2

A

Pertuzumab (PERJETA)

47
Q

rdxthis drug is used to treat metastatic HER2-positive breast cancer (combination therapy) after receiving two or more prior anti-HER2 regimens. mutation/clinical utility is ERBB2

A

Margetuximab (MARGENZA)

48
Q

this drug is used to treat advanced unrespectable or metastatic HER2-positive breast cancer in combination with trastuzumab and capecitabine after receiving one or more prior anti-HER2 based regimens. mutation/clincal utility is ERBB2

A

Tucatinib (TUKYSA)

49
Q

this drug is used as extended adjuvant tx of early stage HER2-positive breast cancer to follow adjuvant trastuzumab-based therapy. mutation/clinical utility is ERBB2

A

Neratinib (NERLYNX)

50
Q

this drug is used to treat HER2-positive advanced or metastatic breast cancer (w/ Capecetabine) after tx with anthracycline and trastuzumab or tx of HR-positive, HER2-positive metastatic breast cancer (w/ Letrozole) in post-menopausal women. mutation/clinical utility is ESR1/ESR2/PGR/ERBB2/HLA-DQA1/HLA-DRB1

A

Lapatinib (TYKERB)

51
Q

this drug is used for treatment of metastatic triple negative breast cancer (mTNBC) where tumours express PD-L1 (CD274). mutations/clincial utility is ERBB2/ESR1/ESR2/PGR/CD274

A

Atezoliumab (TECENTRIQ)

52
Q

does Tucatinib (TUKYSA) cover HER2-negative or positive BC

53
Q

does Alpelisib (PIQRAY) cover HER2-negative or positive BC

54
Q

does Fulvestrant (FASLODEX) cover HER2-negative or positive BC

55
Q

does Lapatinib (TYKERB) cover HER2-negative or positive BC

56
Q

does Neratinib (NERLYNX) cover HER2-negative or positive BC

57
Q

does Palbociclib (IBRANCE) cover HER2-negative or positive BC

58
Q

does Margetuximab (MARGENZA) cover HER2-negative or positive BC

59
Q

does Everoliumus (AFINITOR) cover HER2-negative or positive BC

60
Q

does Olaparib (LYNPARZA) cover HER2-negative or positive BC

61
Q

does Trastuzumab (HERCEPTIN) cover HER2-negative or positive BC

62
Q

does Talazoparib (TALZENNA) cover HER2-negative or positive BC

63
Q

does Abemaciclib (VERENZO) cover HER2-negative or positive BC

64
Q

does Ribociclib (KISQALI) cover HER2-negative or positive BC

65
Q

does Pertuzumab (PERJETA) cover HER2-negative or positive BC

66
Q

these drugs are used to treat ________ cancer
- Olaparib (LYMPARZA)
- Rucaparib (RUBRACA)
- Mirvetuximab Soravtansine (ELAHERE)

A

ovarian
* Olaf’s ruckus mirrored

67
Q

these two drugs are used to treat deleterious gremlin or somatic BCRA-mutated advanced epithelial ovarian, Fallopian tube or primary peritoneal cancer. mutation/clincal utility is BCRA1/BCRA2

A

Olaparib (LYNPARZA) & Rucaparib (RUBRACA)

68
Q

this drug is used to treat folate receptor alpha (FR-alpha) positive, platinum resistant epithelial ovarian, Fallopian tube or primary peritoneal cancer. mutation/clinical utility is FOLR1

A

Mirvetuximab Soravtansine (ELAHERE)

69
Q

these drugs are used to treat _______ cancer
- Dostarlimab (JEMPERLI)
- Lenvatinib (LENVIMA)

A

endometrial
* STAR LENses

70
Q

this drug is used to treat mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum containing regimen
mutation/clinical utility is MLH1/MSH2/MSH6/PMS2/CD274

A

Dostarlimab (JEMPERLI)
* has P in brand name therefore MSI-H/dMMR are “P”resent

71
Q

this drug is used to treat advanced endometrial carcinoma (combination with pembrolizumab), that is NOT micro satellite instability high (MSI-H) or mismatch repair deficient (dMMR) with disease progression following prior systemic therapy.
mutation/clinical utility is MSI/MLH1/MSH2/MSH6/PMS2

A

Lenvatinib (LENVIMA)

72
Q

this drug used used to treat unrespectable or metastatic melanoma with BRAF V600E mutation
mutation/clinical utility: BRAF

A

Vemurafenib (ZELBORAF)
* Debra & Cora’s femurs met Cobi’s bin

73
Q

these 5 drugs are used to treat melanoma with a BRAF V600E or K mutation.
mutation/clinical utility: BRAF

A

Dabrafenib (TAFINLAR)
Encorafenib (BRAFTOVI)
Trametinib (MEKINIST)
Cobimetinib (COTELLIC)
Binimetinib (MEKTOVI)
* Debra & Cora’s femurs met Cobi’s bin

74
Q

this drug is used to treat BRAF V600 mutation-positive unrespectable or metastatic melanoma (combination therapy with cobimetinib and vemurafenib)
mutation/clincal utility is BRAF/CD274

A

Atezolizumab (TECENTRIQ)

75
Q

this drug is used to treat HLA-A02:01-positive adult patients with unrespectable or metastatic UVEAL melanoma (occurs in the tissue of the eye. it is a bisepcific gp100 peptide HLA-A02:01 directed CD3 T-cell engager resulting in direct lysis of uveal melanoma tumour cells
mutation/clinical utility is HLA-A*02:01

A

Tebentafusp (KIMMTRAK)

76
Q

this drug is used to treat gastric adenocarcinoma administered as a component of platinum-containing multi drug chemotherapy regimen.
mutation/clincal utility is DPD (*2A splicing mutation)

A

5-Fluorouracil (FLUOROURACIL)

77
Q

this drug is used to treat unrespectable or metastatic gastrointestinal stroll tutors (GIST) harbouring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations
mutation/clincal utility is PDGFRA

A

Avapritinib (AYVAKIT)

78
Q

this drug is used to treat recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tutors express PD-L1 (CD274)
mutation/clinical utility is CD274

A

Pembrolizumab (KEYTRUDA)

79
Q

this drug is used to treat somatostatin receptor (SSTR)-positive gastroenteropancreatitc neuroendocrine tutors (GEP-NETs)
mutation/clinical utility is SSTR1/SSTR2/SSTR3/SSTR4/SSTR5

A

Lutetium Dotatate (LUTATHERA)

80
Q

this is used for treatment of advanced or metastatic anapaestic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory loco regional treatment options in combination with dabrafenib
mutation/clinical utility is BRAF

A

trametinib (MEKINIST)
* same as melanoma

81
Q

this is used for treatment of advanced or metastatic urothelial carcinoma in patents not eligible for cisplatin-containing chemotherapy and whose tumours express PD-L1 (CD274)
mutation/clinical utility is CD274

A

Atezolizumab (TECENTRIQ)

82
Q

this is used for treatment of advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 mutations and progressed during or following at least one line of platinum-containing chemotherapy
mutations/clinical utility is FGFR2/FGFR3/CYP2C9

A

Erdafitinib (BALVERSA)

83
Q

which CYP2C9 mutations have reduced enzyme activity regarding Erdafitinib (BALVERSA)

A

CYP2C93/3 and 2/3

84
Q

this drug is used to treat gremlin BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC) AND maintenance tx of deleterious or suspected deleterious gBCRAm metastatic pancreatic adenocarcinoma.
mutation/clinical utility is BCRA1/BCRA2

A

Olaparib (LYNPARZA)

85
Q

these two drugs are used to treat unrespectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion
mutation/clinical utility is FGFR2

A

Infigratinib (PEMAZYRE) & PEMIGATINIB (TRUSLETIQ)

86
Q

this is used to treat von Hippel-Lindau (VHL) disease, associated renal cell carcinoma (RCC), central nervous system hemangioblastomas, or pancreatic neuroendocrine tumours (pNET).
mutation/clinical utility is VHL/CYP2C19/UGT2B17

A

Belzutifan (WELIREG)

87
Q

which enzymes are Belzutifan (WELIREG) metabolized by

A

CYP2C19 and UGT2B17

88
Q

this is used to treat solid tutors with a neurotrophic receptor tyrosine kinase gene fusion without a known acquired resistance mutation
mutation/clincal utility is NTRK1/NTRK2/NTRK3

A

Larotrectinib (VITRAKVI)

89
Q

this is used for treatment of leukemia, lymphoma and solid tumour malignancies which causes elevations of uric acid levels
mutation/clincal utility is HLA-B*5801
presence of this increases his for hypersensitivity reactions (SJS/TEN)

A

Allopurinol (ALOPRIM)

90
Q

this is used for treatment of plasma uric acid levels in patients with leukemia, lymphoma and solid tumour malignancies who are receiving therapy to result in tumour lysis.
mutation/clinical utility is G6PD
deficiency of G6PD can result in increased s/e

A

Rasburicase (FASTURTEC)

pharmacogenomics 4860 (10 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions